Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-6 (canceled).

Claim 7 (currently amended). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor ~~The method of claim 1~~ wherein the Src family tyrosine kinase inhibitor is 6-(2,6-dichlorophenyl)-8-methyl-2-(3-methylsulfanylphenylamino)-8*H*-pyrido[2,3-*d*]pyrimidine-7-one.

Claim 8 (currently amended). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor ~~The method of claim 1~~ wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile.

Claim 9 (original). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile has the general Formula (I):

(I)



wherein R^1 is methyl or $-(CH_2)_n-Z$; X^1 is F, Cl, Br, I, and methyl; X^2 is H, F, Cl, Br, I, and methyl; X^3 is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl),

4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

Claim 10 (original). The method of claim 9 wherein R^1 is $-(CH_2)_n-Z$, wherein X^1 and X^2 are both chloro, X^3 is methoxy, n is 3 and Z is 4-morpholinyl.

Claim 11 (previously presented). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile.

Claim 12 (original). The method of claim 8 wherein the 4-anilino-3-quinolinecarbonitrile is 4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

Claim 13 (currently amended). The method of ~~claim 1~~ claim 8 wherein the pharmaceutical composition is administered to the mammal by intraperitoneal injection.

Claim 14 (currently amended). The method of ~~claim 1~~ claim 8 wherein the pharmaceutical composition is administered to the mammal by intravenous injection.

Claim 15 (currently amended). The method of ~~claim 1~~ claim 8 wherein the pharmaceutical composition is administered to the mammal within about 6 hours after the myocardial infarction.

Claim 16 (currently amended). The method of ~~claim 1~~ claim 8 wherein the pharmaceutical composition is administered to the mammal within about 24 hours after the myocardial infarction.

Claim 17 (original). A method for treating a mammal suffering from a myocardial infarction comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.

Claim 18 (previously presented). The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-methylphenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

Claim 19 (previously presented). The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 5-(4-halophenyl) substituted pyrazolo[3,4-*d*] pyrimidine compound.

Claim 20 (previously presented). The method of claim 17 wherein the ATP-competitive Src family tyrosine kinase inhibitor is a 4-(4-haloanilino)-3-quinolinecarbonitrile compound.

Claims 21-36 (canceled).

Claim 37 (currently amended). A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor ~~The method of claim 30~~ wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile having the general Formula (I):

(I)



wherein R^1 is methyl or $-(CH_2)_n-Z$; X^1 is F, Cl, Br, I, and methyl; X^2 is H, F, Cl, Br, I, and methyl; X^3 is H or methoxy; n is 2, 3, 4, or 5; and Z is 4-morpholinyl, 4-(1-methylpiperzinyl), 4-(1-ethylpiperzinyl), 4-(1-propylpiperzinyl), 1-(*cis*-3, 4, 5-trimethylpiperzinyl), 1-piperazinyl, 1-(4-methylhomopiperazinyl), 1-piperidinyl, 4-(1-hydroxypiperidinyl), 2-(1,2,3-triazolyl), 1-(1,2,3-triazolyl), 1-imidazolyl, $-NHCH_2CH_2$-1-morpholinyl, and $-N(CH_3)-CH_2CH_2-N(CH_3)_2$.

Claim 38 (original). The method of claim 37 wherein R^1 is $-(CH_2)_n-Z$, wherein X^1 and X^2 are both chloro, X^3 is methoxy, n is 3 and Z is 4-morpholinyl.

Claim 39 (currently amended). The method of ~~claim 30~~ claim 37 wherein the Src family tyrosine kinase inhibitor is a 4-anilino-3-quinolinecarbonitrile selected from the group consisting of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile and

4-[(2,4-dichlorophenyl)amino]-6-methoxy-7-[3-(morpholin-4-yl)propoxy]-3-quinolinecarbonitrile (SKI-606).

Claim 40 (currently amended). A method for prophylactic treatment of a mammal at risk of myocardial infarction, the method comprising administering to the mammal a prophylactic amount of a pharmaceutical composition comprising a chemical Src family tyrosine kinase inhibitor ~~The method of claim 30~~ wherein the Src family tyrosine kinase inhibitor is an ATP-competitive Src family tyrosine kinase inhibitor having a hydrophobic group that is less than about 6 angstroms in size situated adjacent to an ATP-mimicing heteroaromatic moiety.